AP NEWS
Press release content from BusinessWire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from BusinessWire
Press release content from BusinessWire. The AP news staff was not involved in its creation.

The Global Proton Therapy Market 2018-2022: Projected to Exceed a CAGR of 9% - ResearchAndMarkets.com

January 23, 2019

DUBLIN--(BUSINESS WIRE)--Jan 23, 2019--The “Global Proton Therapy Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.

The proton therapy market will register a CAGR of over 9% by 2022.

The incidence of many cancers such as lung cancer, breast cancer, prostate cancer, colorectal cancer, and stomach cancer is increasing globally.

The associated risk factors of cancers are also on the rise. A significant proportion of the risk of cancer incidence is attributed to the high body mass index, poor dietary habits lack of physical activity, tobacco use and alcohol consumption.

Advantages of proton therapy over standard radiation therapies

Protons can be charged to reach the exact depth where a tumor is located, then stop its further growth. Therefore, proton beams minimize exposure to the nearby healthy tissue surrounding the tumor.

High cost of proton bean therapy and lack of insurance coverage

The high capital costs of proton therapy facilities are restricting their adoption worldwide.

Key Players

IBA Worldwide Hitachi Mevion Medical Systems ProTom International Sumitomo Corporation Varian Medical Systems

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

PART 05: MARKET SIZING

PART 06: FIVE FORCES ANALYSIS

PART 07: MARKET SEGMENTATION BY PRODUCT

Comparison by product Equipment Services Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: REGIONAL LANDSCAPE

Regional comparison Proton therapy market in Americas Proton therapy market in EMEA Proton therapy market in APAC Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

PART 12: MARKET TRENDS

Technological advances Increasing number of clinical trials for indication expansion

PART 13: VENDOR LANDSCAPE

PART 14: VENDOR ANALYSIS

Vendors covered Vendor classification Market positioning of vendors IBA Worldwide Hitachi Mevion Medical Systems ProTom International Sumitomo Corporation Varian Medical Systems

For more information about this report visit https://www.researchandmarkets.com/research/5vbnj4/the_global_proton?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190123005602/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Nuclear Medicine and Radiopharmacology

KEYWORD:

INDUSTRY KEYWORD: HEALTH OTHER HEALTH GENERAL HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/23/2019 11:33 AM/DISC: 01/23/2019 11:33 AM

http://www.businesswire.com/news/home/20190123005602/en

All contents © copyright 2019 The Associated Press. All rights reserved.